U.S., Dec. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07266168) titled 'Efficacy and Safety of Ivarmacitinib in the Treatment of Patients With Polymyalgia Rheumatica' on Dec. 22, 2024.
Brief Summary: The study intends to explore the efficacy and safety of Ivarmacitinib in therapy for polymyalgia rheumatica through a multicenter, randomized, double-blind, placebo-controlled study, and to explore the effectiveness of Ivarmacitinib as an oral glucocorticoid-sparing alternative in the treatment of polymyalgia rheumatica.
Study Start Date: Jan. 20, 2026
Study Type: INTERVENTIONAL
Condition:
Polymyalgia Rheumatics (PMR)
Intervention:
DRUG: Ivarmacitinib tablet
Targets JAK kinases to block signal transdu...